News | July 23, 2024
Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
The innovative ‘Street Safe’ Rapid Testing Kit should be provided to all vendors attending the Food Safety and Certification (FoSTaC) trainings to ensure that safe food is used by the street food vendors across the country
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Subscribe To Our Newsletter & Stay Updated
